In cancer, constitutively high levels of MYC expression can be achieved by translocations rendering MYC under the control of highly active lineage-specific enhancers, such as in Burkitt Lymphoma (BL), or through the acquisition of increased enhancer activity affecting MYC transcription from the endogenous locus. Here, MYC is linked to cancer.